Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2042

Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.

Patents
1,738

Quick answer

1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 11236329

    Compound and method for treating myotonic dystrophy

    Sarepta Therapeutics, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11236171

    Human monoclonal antibodies specific for FLT3 and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11236151

    Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11236055

    Non-systemic TGR5 agonists

    VENENUM BIODESIGN, LLC · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11236111

    Hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11236339

    Modulation of GYS1 expression

    Ionis Pharmaceuticals, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11236122

    Triterpene amine derivatives

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11236360

    Adeno-associated viruses engineered for selectable tropism

    Regents of the University of Minnesota · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11236301

    Thin film cell encapsulation devices

    The Regents of the University of California · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11236056

    Small molecules and methods of reducing injuries caused by radiation or chemicals

    21ST CENTURY THERAPEUTICS, INC. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11236141

    Targeted mutant interferon-beta and uses thereof

    Orionis Biosciences, Inc · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11236402

    Adeno-associated virus virions with variant capsid

    The Regents of the University of California · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11234971

    Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent

    Corcept Therapeutics Incorporated · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11236166

    CD8 binding agents

    Orionis Biosciences, Inc · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11236315

    Thermophile peptidoglycan hydrolase fusion proteins and uses thereof

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11235044

    Cancer vaccines targeting MUC16 and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11236139

    Combination immunotherapy

    The United States Government represented by the Department of Veterans Affairs · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11236102

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11236340

    Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11236080

    Protein kinase inhibitors

    Princeton Drug Discovery, Inc · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11236099

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11236065

    Pyridazinone compounds and uses thereof

    EDGEWISE THERAPEUTICS, INC. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11236044

    Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11235066

    Micelles and methods

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11236338

    Antisense-induced exon2 inclusion in acid alpha-glucosidase

    Sarepta Therapeutics, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11235054

    Multivalent vaccine composition

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11235056

    Glycan-masked engineered outer domains of HIV-1 gp120 and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11234976

    Methods of using pyruvate kinase activators

    Agios Pharmaceuticals, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11234994

    Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

    Benitec Biopharma Limited · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11234967

    Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease

    MEREO BIOPHARMA 1 LIMITED · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11236175

    T cell modifying compounds and uses thereof

    Sangamo Therapeutics, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11234932

    Combination HIV therapeutic

    Aphios Corporation · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11235059

    Afucosylated anti-FGFR2IIIB antibodies

    Five Prime Therapeutics, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11235026

    Methods and compositions for modulating PD1

    Sangamo Therapeutics, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11236161

    Chimeric antigen receptors targeting CD-19

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11235076

    Chelating platform for delivery of radionuclides

    The Regents of the University of California · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. WO 2022025781

    DISPERSION SOLIDE D'OPICAPONE

    BIAL PORTELA & Cª S A [PT] · Granted Thu Feb 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 2022031686

    Treatment of Migraine

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Thu Feb 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11242510

    Mammalian cells devoid of lactate dehydrogenase activity

    The Regents of the University of California · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11241406

    Compositions and methods for acutley raising nitric oxide levels

    Nature's Sunshine Products, Inc. · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11242525

    CRISPR/CAS-related methods and compositions for treating sickle cell disease

    Editas Medicine, Inc. · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11241415

    N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor

    Nektar Therapeutics · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11242400

    CD123 binding proteins and related compositions and methods

    Aptevo Research and Development LLC · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11242380

    Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11242333

    Inhibitors of plasma kallikrein

    KalVista Pharmaceuticals Limited · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11242335

    Fluorine-substituted indazole compounds and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11242377

    Chimeric receptor with ligand binding exodomain and cytokine and T cell signalling endodomains

    AUTOLUS LIMITED · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11241394

    Treating vasculature related diseases or disorders using nanoparticles

    The Regents of the University of California · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2042?

1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.